

Clinical trials of epoetin alfa

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

| Trial | Treatments | Patients | Trials design and methods |
|--|--|--|--------------------------------------|
| epoetin alfa vs placebo | | | |
| HEBE III , 2010 n=263/266 follow-up: 6 weeks | single bolus of 60,000 IU epoetin alfa administered intravenously within three hours after a successful PCI versus control | patients with a first ST-elevation MI and a successful PCI | Parallel groups open the Netherlands |

More details and results :

- increasing hemoglobin concentration for acute myocardial infarction in patients undergoing PCI at <http://www.trialresultscenter.org/go-Q470>

References

HEBE III, 2010:

Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van 't Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010 Nov;31:2593-600 [20802250] [10.1093/eurheartj/ehq304](https://doi.org/10.1093/eurheartj/ehq304)

2 heart failure

| Trial | Treatments | Patients | Trials design and methods |
|--|---|--|------------------------------|
| darbepoetin alfa vs placebo | | | |
| STAMINA-HeFT (Ghali) , 2008 [NCT00049985] n=162/157 follow-up: 27 weeks | darbepoetin alfa SC every 2 weeks for 1 year (target hemoglobin, 14.0+/-1.0 g/dL). versus placebo | Patients with symptomatic HF, left ventricular ejection fraction $\leq 40\%$, and hemoglobin ≥ 9.0 g/dL and ≤ 12.5 g/dL | Parallel groups double blind |

continued...

| Trial | Treatments | Patients | Trials design and methods |
|---|---|---|---------------------------------|
| van Veldhuisen , 2007 [NCT00086086] n=110/55 follow-up: 27 weeks | darbepoetin alfa subcutaneously every 2 weeks for 26 weeks at a starting weight-adjusted dose of 0.75 mcg/kg or a fixed dose of 50 mcg versus placebo | Patients with chronic heart failure (≥ 3 months), left ventricular ejection fraction $\leq 40\%$, and Hb 9.0 to 12.5 g/dL | Parallel groups double blind |
| Ponikowski , 2007 [NCT00117234] n=19/22 follow-up: 27 weeks | Subcutaneous (SC) Darbepoetin Alfa versus subcutaneous placebo | patients with Symptomatic Congestive Heart Failure (CHF) and Anemia | Parallel groups double blind |
| Parissis , 2008 n=21/11 follow-up: | 3-month darbepoetin alpha regimen at 1.5 microg/kg every 20 days plus oral iron versus placebo plus oral iron | CHF patients NYHA II-III, LV ejection fraction [EF] $< 40\%$, hemoglobin level < 12.5 g/dL, serum creatinine level < 2.5 mg/dL | |
| Parissis , 2009 n=30 follow-up: | 3-month darbepoetin alfa regimen at 1.5 microg/kg every 20 days plus oral iron versus placebo plus oral iron | patients with CHF (LV ejection fraction [LVEF] $< 40\%$, hemoglobin < 12.5 g/dl, and serum creatinine < 2.5 mg/dl | |
| Kourea , 2008 n=21/20 follow-up: | 3-month darbepoietin-alpha at 1.5 microg/Kg every 20 days plus iron orally versus placebo plus iron orally | CHF patients NYHA II-III; left ventricular ejection fraction $< 40\%$; hemoglobin < 12.5 g/dl; serum creatinine < 2.5 mg/dl | double blind |

More details and results :

- increasing hemoglobin concentration for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q301>

References

STAMINA-HeFT (Ghali), 2008:

Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. *Circulation* 2008;117:526-35 [18195176]

van Veldhuisen, 2007:

van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. *Eur Heart J* 2007;28:2208-16 [17681958]

Ponikowski, 2007:

Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. *J Am Coll Cardiol* 2007;49:753-62 [17306703]

Parissis, 2008:

Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaïdis I, Ikonomidis I, Filippatos G, Kremastinos DT Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008;155:751.e1-7 [18371487]

Parissis, 2009:

Parissis JT, Kourea K, Andreadou I, Ikonomidis I, Markantonis S, Ioannidis K, Paraskevaïdis I, Iliodromitis E, Filippatos G, Kremastinos DT Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2009;103:1134-8 [19361602]

Kourea, 2008:

Kourea K, Parissis JT, Farmakis D, Paraskevaïdis I, Panou F, Filippatos G, Kremastinos DT Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008;15:365-9 [18525396]

Entry terms: taspoglutide, taspoglutide,